Literature DB >> 15701854

A phase I and pharmacokinetic study of short infusions of UCN-01 in patients with refractory solid tumors.

E Claire Dees1, Sharyn D Baker, Seamus O'Reilly, Michelle A Rudek, Susan B Davidson, Cheryl Aylesworth, Kathy Elza-Brown, Michael A Carducci, Ross C Donehower.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15701854

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


× No keyword cloud information.
  21 in total

1.  Mechanistic Distinctions between CHK1 and WEE1 Inhibition Guide the Scheduling of Triple Therapy with Gemcitabine.

Authors:  Siang-Boon Koh; Yann Wallez; Charles R Dunlop; Sandra Bernaldo de Quirós Fernández; Tashinga E Bapiro; Frances M Richards; Duncan I Jodrell
Journal:  Cancer Res       Date:  2018-05-07       Impact factor: 12.701

Review 2.  New combination therapies with cell-cycle agents.

Authors:  Gagan Deep; Rajesh Agarwal
Journal:  Curr Opin Investig Drugs       Date:  2008-06

3.  Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial.

Authors:  Deepa Sampath; Jorge Cortes; Zeev Estrov; Min Du; Zheng Shi; Michael Andreeff; Varsha Gandhi; William Plunkett
Journal:  Blood       Date:  2005-11-17       Impact factor: 22.113

4.  Simultaneous exposure of transformed cells to SRC family inhibitors and CHK1 inhibitors causes cell death.

Authors:  Clint Mitchell; Hossein A Hamed; Nichola Cruickshanks; Yong Tang; M Danielle Bareford; Nissan Hubbard; Gary Tye; Adly Yacoub; Yun Dai; Steven Grant; Paul Dent
Journal:  Cancer Biol Ther       Date:  2011-08-01       Impact factor: 4.742

5.  Statins synergistically potentiate 7-hydroxystaurosporine (UCN-01) lethality in human leukemia and myeloma cells by disrupting Ras farnesylation and activation.

Authors:  Yun Dai; Payal Khanna; Shuang Chen; Xin-Yan Pei; Paul Dent; Steven Grant
Journal:  Blood       Date:  2007-01-30       Impact factor: 22.113

Review 6.  CHK1 inhibitors in combination chemotherapy: thinking beyond the cell cycle.

Authors:  Paul Dent; Yong Tang; Adly Yacoub; Yun Dai; Paul B Fisher; Steven Grant
Journal:  Mol Interv       Date:  2011-04

7.  GSK-3 beta targets Cdc25A for ubiquitin-mediated proteolysis, and GSK-3 beta inactivation correlates with Cdc25A overproduction in human cancers.

Authors:  Tiebang Kang; Yongkun Wei; Yuchi Honaker; Hiroshi Yamaguchi; Ettore Appella; Mien-Chie Hung; Helen Piwnica-Worms
Journal:  Cancer Cell       Date:  2008-01       Impact factor: 31.743

8.  A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomas.

Authors:  Shivaani Kummar; Martin E Gutierrez; Erin R Gardner; William D Figg; Giovanni Melillo; Janet Dancey; Edward A Sausville; Barbara A Conley; Anthony J Murgo; James H Doroshow
Journal:  Cancer Chemother Pharmacol       Date:  2009-11-06       Impact factor: 3.333

9.  Suppression of antifolate resistance by targeting the myosin Va trafficking pathway in melanoma.

Authors:  María Piedad Fernández-Pérez; María F Montenegro; Magalí Sáez-Ayala; Luis Sánchez-del-Campo; Antonio Piñero-Madrona; Juan Cabezas-Herrera; José Neptuno Rodríguez-López
Journal:  Neoplasia       Date:  2013-07       Impact factor: 5.715

Review 10.  ATR/CHK1 inhibitors and cancer therapy.

Authors:  Zhaojun Qiu; Nancy L Oleinick; Junran Zhang
Journal:  Radiother Oncol       Date:  2017-10-18       Impact factor: 6.280
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.